Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Helix BioPharma ( (TSE:HBP) ) just unveiled an update.
Helix BioPharma announced its decision not to proceed with the proposed equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited, despite receiving shareholder approval. The decision was made after evaluating market conditions and aligning with long-term corporate objectives, as the facility no longer fits Helix’s capital strategy. The company remains committed to securing necessary capital through alternative financing to advance its clinical programs and meet corporate goals.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.
Helix BioPharma faces significant financial challenges with no revenue and continuous losses, resulting in a low financial performance score. Weak market momentum and poor valuation metrics further dampen the stock’s attractiveness. Recent corporate events provide some strategic hope, but are not enough to overcome the fundamental financial issues.
To see Spark’s full report on TSE:HBP stock, click here.
More about Helix BioPharma
Helix BioPharma is a clinical-stage oncology company focused on developing innovative treatments for hard-to-treat cancers. Their leading product, Tumor Defense Breaker™ L-DOS47, is an antibody-enzyme conjugate aimed at enhancing the effectiveness of existing cancer therapies. The company also has two pre-IND candidates, LEUMUNA™ and GEMCEDA™, targeting post-transplant leukemia relapse and advanced cancers, respectively.
Average Trading Volume: 10,687
Technical Sentiment Signal: Hold
Current Market Cap: C$103.8M
For an in-depth examination of HBP stock, go to TipRanks’ Overview page.